Morgan Stanley Spectrum Pharmaceuticals Inc Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.65 - $1.31 $24,891 - $50,165	-38,294 Reduced 3.34%	1,107,825 $1.06 Million
Q1 2023 May 15, 2023	SELL	$0.38 - $1.07 $47,715 - $134,357	-125,568 Reduced 9.87%	1,146,119 $859,000
Q4 2022 Feb 14, 2023	SELL	$0.32 - $0.52 $77,088 - $125,269	-240,902 Reduced 15.93%	1,271,687 $470,000
Q3 2022 Nov 14, 2022	SELL	$0.43 - $1.56 $116,316 - $421,986	-270,504 Reduced 15.17%	1,512,589 $650,000
Q2 2022 Oct 27, 2022	BUY	$0.7 - $1.4 $88,074 - $176,149	125,821 Added 7.59%	1,783,093 $1.39 Million
Q2 2022 Aug 15, 2022	BUY	$0.7 - $1.4 $88,074 - $176,149	125,821 Added 7.59%	1,783,093 $1.39 Million
Q1 2022 Oct 27, 2022	SELL	$0.63 - $1.59 $79,267 - $200,055	-125,821 Reduced 7.06%	1,657,272 $2.14 Million
Q1 2022 May 13, 2022	SELL	$0.63 - $1.59 $687,347 - $1.73 Million	-1,091,027 Reduced 39.7%	1,657,272 $2.14 Million
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.42 $1.31 Million - $2.5 Million	1,031,749 Added 60.11%	2,748,299 $3.49 Million
Q3 2021 Nov 15, 2021	BUY	$2.15 - $3.82 $3.69 Million - $6.56 Million	1,716,550 New	1,716,550 $3.74 Million

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.